Traders should monitor upcoming clinical data catalysts in 1Q 2026 for WVE-007 and WVE-006, which could drive positive sentiment despite weak financials. The strong cash position reduces near-term dilution risk, but the stock may remain volatile based on clinical trial outcomes.
WVE drugs
WVE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 26 $15.36entry
- T+1 · 9mo ago −9.31%α −8.86% · $13.93
- T+5 · 9mo ago −14.06%α −12.94% · $13.20
- T+20 · 8mo ago −59.64%α −53.23% · $6.20
- T+60 · 6mo ago −58.20%α −65.95% · $6.42
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Wave Life Sciences reported a significant year-over-year decline in revenue and a shift from net income to a substantial net loss, driven by lower collaboration revenue. However, the company highlighted positive clinical progress across its pipeline, including obesity drug WVE-007 showing fat loss comparable to GLP-1s, strong data for WVE-006 in AATD, and a well-capitalized position with cash runway into 3Q 2028. The negative financials are offset by multiple upcoming clinical catalysts and pipeline advancements.
Key Financial Metrics
Key Facts
- Revenue dropped 79.7% YoY to $17.2M in Q4 2025 and 60.5% for the full year to $42.7M, primarily due to reduced GSK milestone payments.
- Net loss was $53.2M in Q4 2025 vs. $29.3M net income in Q4 2024; full-year net loss was $204.4M vs. $97.0M in 2024.
- Cash and equivalents increased to $602.1M as of Dec 31, 2025, providing runway into 3Q 2028.
- WVE-007 (obesity) showed fat loss similar to GLP-1s at three months in interim data, with muscle preservation, and plans for Phase 2a trials in 2026.
- WVE-006 (AATD) demonstrated key treatment goals met, including dynamic AAT production, with regulatory feedback on accelerated approval expected mid-2026.
- WVE-N531 (DMD) remains on track for NDA filing in 2026 for accelerated approval.
Financial Impact
Revenue declined by $66.5 million in Q4 and $65.6 million for the full year; net loss increased by $82.5 million in Q4 and $107.4 million for the full year.
Segment Breakdown
| Segment |
|---|
| obesity |
| AATD |
| DMD |
Risk Factors
- Heavy reliance on partnership revenue (GSK) creates financial volatility.
- Clinical trial failures could significantly impact the stock, given the pipeline-driven valuation.
- Dilution risk if additional funding is needed beyond 2028, though current cash runway is sufficient.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-073437 |
| Document: d103046dex992.htm | 0001193125-26-073437 |
| Document: d103046d8k.htm | 0001193125-26-073437 |
| Document: 0001193125-26-073437-index-headers.html | 0001193125-26-073437 |
| Document: 0001193125-26-073437-index.html | 0001193125-26-073437 |
| Document: 0001193125-26-073437.txt | 0001193125-26-073437 |
Track record
16 reports on WVE
3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +17.42% at T+5 after the Mar 26, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.13 to $2.87 Now $2.87 −8.31% ▼ −8.31% −6.40% vs SPY
- Oct 27, 202620d ago SC 13G Neutral 4/10 Entry $3.64 to $3.63 Now $2.87 −21.15% ▼ −0.27% +0.11% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $3.45 to $3.64 Now $2.87 −16.81% ▲ +5.51% +5.16% vs SPY
- Oct 27, 202620d ago 8-K Bullish 6/10 No price data
- Oct 27, 202620d ago Press Release Neutral 5/10 Entry $3.45 to $3.64 Now $2.87 −16.81% ▲ +5.51% +5.16% vs SPY
- Oct 14, 20264w ago DEF 14A Neutral 4/10 Entry $3.19 to $3.13 Now $2.87 −10.03% ▼ −1.88% −0.77% vs SPY
- Sep 30, 20266w ago Press Release Bullish 5/10 Entry $3.70 to $3.88 Now $2.87 −22.43% ▲ +4.86% +4.69% vs SPY
- Aug 13, 202613w ago Insider Cluster Neutral 3/10 Entry $5.41 to $5.09 Now $2.87 −46.95% ▼ −5.92% −5.44% vs SPY
- May 18, 202626w ago Press Release Bullish 7/10 Entry $6.14 to $6.19 Now $2.87 −53.26% ▲ +0.81% −0.23% vs SPY
- Apr 28, 202628w ago 8-K Bullish 7/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers